Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.72 (market cap $5.07B), while iShares 1 3 Year Treasury Bond ETF trades at $81.95. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | SHY | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Fixed Income |
52-Week High | $29.41 | $83.18 |
52-Week Low | $20.06 | $81.77 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.955, up 0.12% on the day, with a bearish technical signal driven by moving averages. Recent news highlights institutional accumulation, including Barry Investment Advisors increasing its stake by 48.1% in Q2 2026 (SEC filing, August 10, 2026), amid fluctuating Treasury yields influenced by inflation data and Middle East tensions. The ETF maintains a steady dividend schedule, with recent payouts of $0.24-$0.25 per share.
Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income stability but limited growth. Risks include Fed policy shifts and oil-price volatility, while institutional buying signals defensive positioning. The neutral oscillator reading suggests short-term consolidation near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
